Calypte HIV test for same-day use cleared in US:
This article was originally published in Clinica
The US FDA has cleared Calypte Biomedical's serum HIV-1 assay for same-day (five-hour response) use, supplementing its existing licence under which it can be sold as an overnight test. The assay confirms the presence of HIV-1 antibodies in serum by Western blotting. Calypte, of Alameda, California, assigned Carter-Wallace the exclusive US marketing rights for the test in September. It also appointed distributors for 13 countries in Asia, Eastern Europe and the Middle East.
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.